cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine
Stage IV Lung Cancer AJCC v8
University of WashingtonvaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
303 Active assets in the Stage IV Lung Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin SystImmune Inc. | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II University of Vermont | Phase 4 | BB |
Nivolumab University of Chicago | Phase 4 | BB |
ETOPOSIDE SystImmune Inc. | Phase 3 | BB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BB |
View all 50 →
Same molecule, other indications
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →